Stock Update (NYSE:BMY): U.S. Food and Drug Administration Approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults

[Business Wire] – Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. . . . → Read More: Stock Update (NYSE:BMY): U.S. Food and Drug Administration Approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults Similar Articles: Market Update: AbbVie Inc (NYSE:ABBV) – U.S. FDA approves AbbVie all-oral hepatitis C treatment Stock Update (NYSE:BMY): UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment Market Update (NYSE:LLY): New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies